Rapid Benzodiazepine Detoxification Using Flumazenil - 1

Yale University

Status and phase: Completed; Phase 2

Conditions: Substance-Related Disorders

Treatments: Drug: Flumazenil

Study type: Interventional

Funder types: Other; NIH

Identifiers

NCT00000246

R01-08265-1

R01DA008265 (U.S. NIH Grant/Contract)

NIDA-08265-1

Details and patient eligibility

About

The purpose of this study is to verify the hypothesis that the benzodiazepine antagonist, flumazenil, will reduce acute benzodiazepine withdrawal.

Enrollment: 10 patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Please contact site for information.